Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025
Published on 05/29/2025 at 11:46
Share
Roivant Sciences Ltd. reported earnings results for the fourth quarter and full year ended March 31, 2025. For the fourth quarter, the company reported sales was USD 7.57 million compared to USD 9.02 million a year ago. Net loss was USD 206.48 million compared to USD 151.12 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.08 a year ago. Diluted loss per share from continuing operations was USD 0.29 compared to USD 0.08 a year ago. Basic loss per share was USD 0.29 compared to USD 0.19 a year ago. Diluted loss per share was USD 0.29 compared to USD 0.19 a year ago.
For the full year, sales was USD 29.05 million compared to USD 32.71 million a year ago. Sales was USD 29.05 million compared to USD 32.71 million a year ago. Net loss was USD 171.98 million compared to net income of USD 4,348.93 million a year ago. Net loss was USD 171.98 million compared to net income of USD 4,348.93 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to basic earnings per share from continuing operations of USD 5.95 a year ago. Basic loss per share from continuing operations was USD 0.75 compared to basic earnings per share from continuing operations of USD 5.95 a year ago. Diluted loss per share from continuing operations was USD 0.75 compared to diluted earnings per share from continuing operations of USD 5.61 a year ago. Diluted loss per share from continuing operations was USD 0.75 compared to diluted earnings per share from continuing operations of USD 5.61 a year ago. Basic loss per share was USD 0.24 compared to basic earnings per share of USD 5.55 a year ago. Basic loss per share was USD 0.24 compared to basic earnings per share of USD 5.55 a year ago. Diluted loss per share was USD 0.24 compared to diluted earnings per share of USD 5.23 a year ago. Diluted loss per share was USD 0.24 compared to diluted earnings per share of USD 5.23 a year ago.
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
